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Exposure toMycobacterium tuberculosis (Mtb)may lead to active or latent tuberculosis, or clearance ofMtb,
depending essentially on the quality of the host's immune response. This response is initiated through the
interaction of Mtb cell wall surface components, mostly glycolipids, with cells of the innate immune sys-
tem, particularly macrophages (M4s) and dendritic cells (DCs). The way M4s and DC alter their cytokine
secretome, activate or inhibit different microbicidal mechanisms and present antigens and consequently
trigger the T cell-mediated immune response impacts the host immune response against Mtb.
Lipoarabinomannan (LAM) is one of the major cell wall components of Mtb. Mannosyl-capped LAM
(ManLAM), and its related cell wall-associated types of glycolipids/lipoglycans, namely phosphatidylino-
sitol mannosides (PIMs) and lipomannan (LM), exhibit important and distinct immunomodulatory prop-
erties. The structure, internal heterogeneity and abundance of these molecules vary between Mtb strains
exhibiting distinct degrees of virulence. Thus ManLAM, LM and PIMs may be considered crucial Mtb-
associated virulence factors in the pathogenesis of tuberculosis. Of particular relevance for this review,
there is controversy about the speciﬁc immunomodulatory properties of these distinct glycolipids,
particularly when tested as puriﬁed molecules in vitro. In addition to the variability in the glycolipid
composition conﬂicting reports may also result from differences in the protocols used for glycolipid
isolation and for in vitro experiments including immune cell types and procedures to generate them.
Understanding the immunomodulatory properties of these cell wall glycolipids, how they differ be-
tween distinct Mtb strains, and how they inﬂuence the degree of Mtb virulence, is of utmost relevance to
understand how the host mounts a protective or otherwise pathologic immune response. This is
essential for the design of preventive strategies against tuberculosis. Thus, since clarifying the contro-
versy on this matter is crucial we here review, summarize and discuss reported data from in vitro
stimulation with the three major Mtb complex cell wall glycolipids (ManLAM, PIMs and LM) in an
attempt to conciliate the conﬂicting ﬁndings.
© 2015 Elsevier Ltd. All rights reserved.Contents
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Mycobacterium tuberculosis (Mtb) is the causative agent of
tuberculosis (TB). While infection with Mtb may result in active
disease, in most cases the bacteria persist in the infected host
without open signs of disease [1]. The different outcomes of
exposure to Mtb, active TB, latent TB or no disease, are known to
depend to a large extent on the interplay between the invadingMtb
and the host immune system.
Both innate and acquired branches of the immune response are
essential in the battle against Mtb [2,3]. Importantly, the very ﬁrst
steps of the innate immune response are crucial to modulate the
overall innate aswell as the acquired immune response [4]. Mtb cell
wall components exhibit important speciﬁc pathogen-associated
molecular patterns (PAMPs); the innate immune response is initi-
ated upon recognition of these molecules by pattern recognition
receptors (PRRs), expressed mostly by macrophages (M4s) and
dendritic cells (DCs). Several classes of PRRs have been implicated in
the recognition of Mtb, including Toll-like receptors (TLRs) and C-
type lectin receptors (CLRs), such as DC-speciﬁc intercellular adhe-
sion molecule-3 grabbing nonintegrin (DC-SIGN) [5]. There are
several TLR and non-TLR PRRs involved in activation ofM4s andDCs
by Mtb. Among these, an impressive body of data shows the
importance of TLR2, while reports on the involvement of other TLRs
are still controversial [6e9]. Via TLRs and/or nucleotide-binding
oligomerization domain receptors, intracellular signals are
induced inM4s and DCs, initiating a local immune response leading
to cytokine production and increased numbers of M4s and DCs in
the infected tissue and draining lymph nodes. Following activation
by cytokines and innate receptor agonists, infected M4s elicit direct
bactericidal effector functions. DCs are known to phagocytose the
bacteria in infected tissues , migrate to draining lymph nodes, and
initiate the adaptive immune response by priming naïve T and B
lymphocytes. Here, the maturation/activation state of DCs has been
shown to play an important role in their response to infection and in
the subsequent acquired immune response [10].
Several cell wall associated mycobacterial glycolipids/lip-
oglycanse play a crucial role in the immunomodulation induced by
Mtb by eliciting distinct immune responses and activating/
repressing different immune cascades [11]. In particular lip-
oarabinomannan (LAM) has been studied for itse Lipoglycan or lipoglycoconjugate might be chemically more accurate terms to
describe LM and LAM, however since all are based on a man-
nosylphosphatidylinositol anchor, the generic term glycolipid may be applicable to
all three ligand classes. For the sake of simplicity we will use the term glycolipid.
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addition to LAM, its precursors lipomannan (LM) [12e14] and
phosphatidyl-myo-inositol mannosides (PIMs) [12e15] have been
shown to have potent modulatory effects in vitro on cells of the
immune system (Figure 1). LAM, LM and PIMs are all prevalent
components of the mycobacterial cell wall [16]. In addition to the
LAM/LM/PIM family of molecules the cell wall is composed of
other lipids and glycolipids such as trehalose containing and
phenolic glycolipids, as well as glyco- and lipo-proteins, which
also contribute to the immune response. However these will not
be the focus of this review.
In 1989 the major cell wall associated glycolipid, mannose-
capped LAM (ManLAM) from Mtb was reported to stimulate the
release of pro-inﬂammatory cytokines such as tumour necrosis
factor (TNF) from human and murine M4s [17]. However, in sub-
sequent publications, the reported effects of ManLAM on M4s and
DCs were not consistent, in respect to activation and release of pro-
inﬂammatory cytokines, such as interleukin (IL)-12 and IL-6
(Table 1), and expression of co-stimulatory (CD80, CD86) and an-
tigen presenting molecules (MHC class II) (Table 2). In summary,
over the last three to four decades many conﬂicting results on the
immunomodulatory effects of ManLAM and other LAMs and their
precursor molecules have accumulated, leaving the scientiﬁc
community in confusion.
These and other complex and sometimes contradictory reported
actions of Mtb associated cell wall glycolipids prompted us to
analyse the possible reasons underlying those discrepant results. A
deep analysis of the literature revealed that several factors
contribute to such diverse effects and also to the lack of consistency.
On one hand there are very important differences between the
immunomodulatory abilities of the different glycolipids (PIM, LM,
LAM and ManLAM and potentially others) present in the Mtb cell
wall [18]; the analysis of the different molecules separately is
essential if one aims to understand howMtb glycolipsmodulate the
host immune response. On the other hand, the same glycolipid may
vary in composition between distinct Mtb complex strains. In
addition to this inherent glycolipid diversity, differences in the
protocols used to perform the experiments might also have
contributed to the lack of consistency in the published results.
Differences include variables associated with distinct protocols to
grow the bacteria (which have a strong inﬂuence on the compo-
sition of the bacterial cell wall glycolipids); diverse strategies to
isolate the distinct glycolipids (which have an effect on the
composition/structure of the isolated glycolipids) compounded by
the amphiphilic/amphipathic nature of LM and LAM; differences in
the immune cells used (M4s, monocytes and DC; mouse or human
origin); and on the protocols used to isolate/stimulate/differentiate, and its related glycolipids, induce divergent and opposing immune
y and experimental variations, Tuberculosis (2015), http://dx.doi.org/
Figure 1. Schematic ﬁgure of proposed structures of ManLAM, LM and PIMs based on current data [29,42,88e92]. There is some question as to the exact attachment points of the
arabinan portions to the LM core in LAM, and the number of Araf residues and their arrangement can vary.
Table 1
Cytokine production by monocytes/M4s and DCs exposed to M. tuberculosis complex ManLAM.
Publication/year Cell type Strains Origin of ManLAM preparation TNF IL-6 IL-12 IL-10
Monocytes/M4s
[17] 1989 PM mouse H37Rv Inhouse
PM mouse Mtb strain not speciﬁed CSU
Monocytes human H37Rv Inhouse
Monocytes human Mtb strain not speciﬁed CSU
[49] 1992 PM mouse Erdman CSU
[57] 1993 BMM mouse Erdman CSU
[50] 1993 PM mouse Erdman CSU ( )*
[51] 1993 PM mouse H37Rv Inhouse
PM mouse Erdman CSU ( )
BMM mouse H37Rv Inhouse
[80] 1995 BMM mouse H37Rv CSU ( )
Erdman CSU
[59] 1996 Monocytes human Erdman/H37Rvy CSU ( )
[58] 1997 M4 murine cell line J774 Strain not speciﬁed CSU contract N01AL-25147
[72] 1998 Human monocyte derived cell line THP-1 Erdman CSU
[48] 2000 AM human H37Rv CSU
[7] 2004 BMM mouse H37Rv CSU/CNRS ( )
BCG NRS ( )
[12] 2004 BMM mouse H37Rv CSU
[77] 2006 AM mouse Mtb Ayoama B strain Nacalai Tesque Co
[93] 2010 M4 human H37Rv OSU
[83] 2011 PM mouse H37Rv KI
DCs
[62] 1997 DC human BCG “parietal” CNRS
BCG “cellular” CNRS ( )
[64] 2007 DC human H37Rv CNRS ( ) ( ) ( )
[65] 2011 DC human H37Rv CSU
[18] 2012 DC human H37Rv KI
M. bovis KI
[66] 2014 BMDC mouse Mtb strain not speciﬁed Not stated
Abbreviations used: AM e alveolar M4s; BMM e bone marrow derived M4s; BMDC e bone marrow derived DC; CNRS e Centre National de la Recherche Scientiﬁque; CSU e
Colorado State University; KI e Karolinska Institutet; OSU e Ohio State University; PM e peritoneal M4s.
Symbols used: Increased production; Decreased production; No difference.
* Brackets around arrows mean weak response.
y Not clear which preparation was used in which experiment.
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Table 2
Activation/maturation of M4s and DCs exposed to ManLAM.
Publication/year Cell type Strain Origin of ManLAM Activation/
maturation
Activation tested Inhibition of IFN-g
induced activation
M4s
[52] 1988 PM mouse Mtb strain unknown CSU Tumoricidal and
Toxoplasmacidal activity
Yes
[53] 1990 PM mouse Mtb strain unknown CSU Tumoricidal activity Yes
[54] 1991 U937 M4-like cell line Mtb strain unknown CSU Protein kinase C activity Yes
[50] 1993 PM mouse Erdman CSU ( )* Toxoplasmacidal activity Yes
[55] 1995 BMM mouse Erdman CSU ( ) NF-kB NT
[7] 2004 BMM mouse BCG CNRS ( ) CD40, CD86 NT
DCsa
[63] 2003 DC human Strain unknown CSU contract
N01AL-75320
CD80, CD83, CD86 and HLA-DR NT
[64] 2007 DC human H37Rv CNRS CD83 and CD 86 NT
[65] 2011 DC human H37Rv CSU CD83 and CD86 NT
[18] 2012 DC human H37Rv KI CD80, CD86 and MHC II NT
Abbreviations used: BMM e bone marrow derived M4s; CNRS e Centre National de la Recherche Scientiﬁque; CSU e Colorado State University; KI e Karolinska Institutet; NT
e not tested; PM e peritoneal M4s.
Symbols used: Increased; Decreased; No difference.
* Brackets around arrows mean weak reactions.
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cells, receptor (PPR) equipment and signalling pathways that are
active). To all of these variables in the protocols used by distinct
laboratories one needs still to consider the use of preparations of
allegedly pure speciﬁc glycolipids that have been shown to be
contaminated with other glycolipids or even other components
[18].
In an attempt to bring some clariﬁcation to this important issue
we here review the reported effects of the three major mycobac-
terial cell wall glycolipids, ManLAM, LM and PIMs on the matura-
tion and cytokine proﬁles of murine and human M4s and DCs,
dissecting the differences associated with the structure/composi-
tion of these molecules as well as the discrepancies that might
result from experimental conditions.
Although this review focuses on the effects of glycolipids on
M4s and DCs it is of relevance to stress that these molecules also
exert effects on other important cells in the immune response
against Mtb. This is the case for neutrophils that in combination
with alveolar M4s are recognized as the ﬁrst line of defence against
pulmonary TB. Several studies show how the very initial response
of neutrophils, in particular the ability to trigger apoptosis, in-
ﬂuences the overall subsequent immune response [19]. Most of
these studies address how neutrophils respond to whole bacteria,
which seems necessary to trigger apoptosis of neutrophils [20].
However, puriﬁed glycolipids, in particular LAM, but not PIM, have
been shown to be sufﬁcient to induce other functions, namely
TRAIL release by neutrophils [21]. T cells have been mostly inves-
tigated as the main players of the acquired immune response
triggered by Mtb components presented in the context of antigen
presenting molecules. However, puriﬁed glycolips are also known
to directly inﬂuence T cells. LAM and/or more speciﬁcally mannose
capped lipoarabinomannan (ManLAM), have been shown to
directly inhibit the activation/proliferation of T cells [22e24] and to
speciﬁcally modulate the cytokine proﬁle released by these cells
[25].
LAMs are found in the cell wall of all mycobacterial species [26].
Generally they present a tripartite structure composed of an acyl-
ated mannosylphosphatidylinositol (MPI) anchor, attached to a
poly-mannosyl backbone with arabinan branches, and different
capping motifs [16,27] (Figure 1). ManLAM is most abundant in
slowly growing pathogenic species of the Mtb complex, i.e. or-
ganisms causing TB, in particular Mtb and Mycobacterium bovisPlease cite this article in press as: K€allenius G, et al., Lipoarabinomannan
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M. bovis (BCG). Other structural variants of LAM are PILAM
(formerly called AraLAM [29]) with arabinan chains terminated
with phospho-inositol motifs, such as in Mycobacterium smegmatis
[30] or AraLAM devoid of any capping motifs, such as in Mycobac-
terium chelonae, are typical of less pathogenic mycobacteria, [29].
PIMs and LM are direct precursors of LAM; the phosphatidyli-
nositol dimannosides (PIM2) and hexamannosides (PIM6) are the
two most abundant classes of PIMs found in BCG and Mtb H37Rv.
PIM2 gives rise to the highly mannosylated LM molecule, which is
further extended by the arabinan domain to form LAM. They are
non-covalently attached to the plasma membrane through their
phosphatidyl-myo-inositol anchor, and extend to the exterior of the
cell wall [16] although there is evidence for partial placement in the
mycolic acid-rich mycobacterial outer membrane [31,32]. By
contrast PIM6 appears to be an end product [16]. LAM/LM are not
single chemical entities and the basis of their structural heteroge-
neity may be due to variations in e.g. the number and nature of the
acyl groups, length and branching of the mannan core, or arabinan
component [33]. LAM, LM and PIM exhibit various acyl forms, for
example the “PIM6 family” of BCG corresponds to a mixture of 10
and 12 acylated forms [14].
Cell wall glycolipids play a part in the distinct immune
response elicited by different Mtb-complex strains
It is becoming increasingly apparent that different Mtb-
complex strains induce different responses by the host's im-
mune cells [34,35]. For example themagnitude and patterns of the
cytokine responses in Mtb infected M4s is highly mycobacterial
strain-dependent [7,36,37]. Human alveolar M4s infected with
the virulent laboratory strainMtb H37Rv orM. bovis producemore
TNF than those infected with the more attenuated Mtb H37Ra
strain or with BCG [38]. In turn, humanM4s infected with virulent
clinical Mtb isolates produce more TNF than those infected with
Mtb H37Rv [37]. Strains of the Mtb Beijing lineage, deﬁned
by speciﬁc RD deletions, are differentially recognized by TLRs
and trigger different immune responses [36]. The mechanism
responsible for these strain-related differences is most likely
multi-factorial, but may in part be dependent on the different
nature and relative amounts of the cell wall-associated glycolipid
molecules produced by different mycobacterial strains. Small but, and its related glycolipids, induce divergent and opposing immune
y and experimental variations, Tuberculosis (2015), http://dx.doi.org/
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Mtb-complex strains may account for important differences in the
immune response [14,33,39]. It has, for example, been shown that
ManLAMs from H37Rv, Mtb Erdman and BCG differ in structural
aspects [28] such as mannosyloligosaccharide capping content
[40], which might be important for biological function. Mtb-
complex strains containing truncated and more branched forms
of mannose-capped ManLAM result in their low association with
the M4 mannose receptor [39]. Thus LAM from Mtb H37Rv and
BCG were reported to be heterogeneous with respect to arabinan
and mannan domains and to differ in abundance of acyl-isoforms
[41]. Variations in mannose-capped terminal arabinan motifs
have been observed in LAMs from clinical isolates of Mtb [42],
which may well be responsible for the different biological activ-
ities. Cytokine expression is inﬂuenced by the acylation state of
LM ligands [43] and there is a relationship between the overall
charge of the ManLAM molecule and its capacity to stimulate the
production of interferon-g (IFN-g) in different CD1b-restricted T-
cell lines [44]. There are also differences in the ability of LAM from
different Mtb strains (Erdman, H37Rv and H37Ra) to mediate
adherence to M4s [45].
Culture conditions of the Mtb-complex strains have been shown
to affect the composition of the isolated glycolipids [46,47]. Hence,
in order to dissect the role of mycobacteria derived molecules on
the innate immune responses not just the choice of mycobacterial
strain for isolation of the glycolipids is of utmost importance but
also the protocol used to grow the bacteria and isolate the glyco-
lipids (discussed in more detail ahead).
M4 activation/maturation and cytokine production upon exposure
to ManLAM from various sources
ManLAMs puriﬁed from Mtb complex were, in early studies
in the late 1980s early 1990s, found to stimulate the production
of pro-inﬂammatory cytokines, in particular TNF, by both hu-
man [17,48] and mouse [17,49e51] M4s (Table 1). However, the
reported magnitude of the TNF secretion varied greatly
between studies. ManLAM has also been reported to affect other
M4 functions, such as inhibition of various IFN-g mediated
microbicidal and tumoricidal activities [52e54], but it has also
been reported that ManLAM can trigger the microbicidal activity
of IFN-g-primed M4s [50].
In the report by Moreno et al. [17] in 1989 treatment of the
ManLAM with alkali greatly reduced the TNF-secreting activity,
suggesting that O-acyl groups were involved. A few years later
ManLAM derived from the “virulent” laboratory Mtb strain Erdman
was reported to be a weak stimulator of a pro-inﬂammatory
response in respect to TNF production [49] and stimulation of NF-
kB [55] in mouse M4s compared to LAM isolated from the so
called “avirulent” H37Ra laboratory strain. Some of the discordant
information about the effect of ManLAM on the induction of a pro-
inﬂammatory response by M4s apparently stem from these early
papers.
Erdman ManLAM induces low/no pro-inﬂammatory response
ManLAM prepared from the Mtb Erdman strain [56] was used
in many of the early studies analyzing M4 activation (Table 2)
and cytokine production (Table 1). Erdman ManLAM prepara-
tions were repeatedly reported to either fail to induce the pro-
duction of TNF in mouse [49,50,57] M4s, or to produce very low
amounts of TNF (Table 1), not only compared to LAM (AraLAM,
see ahead) prepared from the so called “avirulent” H37Ra labo-
ratory strain [49e51,57] (see ahead) but also compared to Man-
LAM from H37Rv [51]. When ManLAM preparations from thePlease cite this article in press as: K€allenius G, et al., Lipoarabinomannan
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H37Rv ManLAM was found to induce higher amounts of TNF
compared to that from Erdman [51] in murine peritoneal M4s.
ManLAM from Erdman also failed to induce IL-12p40 in mouse
M4s [58]. Reports suggest that IFN-g activation is needed to
stimulate TNF production through stimulation of peritoneal M4s
with Erdman ManLAM [50], while in other studies bone marrow
derived cells were unresponsive to Erdman ManLAM despite IFN-
g activation [57].
The AraLAM that in early papers was said to be from H37Ra was
from a rapid growing strain
Part of the discordant results from the early in vitro experiments
[13,49,50] stems from the fact that the AraLAM (without mannose
cap, and a potent inducer of TNF) that in these early papers was said
to stem from the “avirulent” attenuated H37Ra strain in fact came
from a rapidly growing mycobacteria species, presumably
M. smegmatis [28,29], in which LAM is not mannose-capped (while
LAMs from both H37Rv and H37Ra are mannose capped) [29]. In
general, LAM lackingmannose capping (AraLAM/PILAM) stimulates
higher TNF production than ManLAM from Mtb-complex strains
[59], indicating that the amount of mannose capping may be
responsible for the pro-inﬂammatory capacity of a particular strain.
Indeed the Erdman Mtb strain is reported to be signiﬁcantly more
mannose-capped, compared to H37Rv [40] and H37Ra [29,40],
which may be part of the explanation for its low/absent pro-
inﬂammatory activity. However, although the loss of LAM
mannose caps in a mutant of BCG induced a somewhat higher
production of TNF in M4s, as compared to the wild type strain, it
did not affect the production of TNF in DCs [60]. Neither did the lack
of the mannose cap in aMtbmutant affect its virulence in mice [60]
an observation that deserves attention in the future.
ManLAM from Mtb H37Rv drives maturation/activation of human
DCs
The interaction of ManLAM with DCs, in particular with human
DCs, is less well studied than the interaction with M4s [61e63]. It
was demonstrated that a highly puriﬁed H37Rv ManLAM was a
potent activator of human DCs showing several similarities with
LPS in respect to DC cytokine production and cell maturation proﬁle
[18] (Table 2). These observations are in agreement with the ﬁnd-
ings by Dulphy et al. [64] where DCs were activated with ManLAM
from H37Rv, displaying a dose-dependent maturation phenotype,
in terms of CD83 and CD86 expression but in contrast to the ﬁnd-
ings by Geijtenbeek et al. [63] and Wu et al. [65] where ManLAM
did not induce DCmaturation. The reason for this discrepancy is not
clear but it could be hypothesized that also here strain-associated
differences in the relative abundance of molecular forms of Man-
LAM or/and degree of purity of the preparation used could
contribute to the observed divergent effects on DC maturation.
Cytokine response of DCs stimulated by ManLAM
ManLAM from H37Rv was shown to induce a strong pro-
inﬂammatory cytokine response in human DCs, manifested by
TNF, IL-6, and IL-12 release [18] (Table 1). Similar results were re-
ported in a recent study using mouse cells, where ManLAM acti-
vated bone-marrow-derived DC were shown to produce pro- and
anti-inﬂammatory cytokines via a C-type lectin receptor, Dectin-2
[66]. Thus ManLAM induces the production of TNF and IL-6 as
well as the anti-inﬂammatory cytokine IL-10. In a study by Dulphy
et al. [64], ManLAM-activated DCs produced the pro-inﬂammatory
cytokines IL-6 and IL-8 but at a lower amount compared with cells, and its related glycolipids, induce divergent and opposing immune
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tional IL-12p70 heterodimer.
In an earlier study by Nigou et al. different types of ManLAM
obtained from BCG were reported to have different stimulatory
capacity [62]. While the cell wall-associated preparation, “parietal”
ManLAM, was shown to induce TNF and IL-8 production, the cell
membrane-associated “cellular” ManLAM preparation did not
induce a clear production of TNF or IL-8 [62]. The “parietal” type
was reported to be uniquely O-acylated andMan-capped to a larger
extent than the “cellular” type [62].
Considering its TNF stimulatory effect, the H37Rv ManLAM
preparation investigated by Mazurek et al. [18] behaved as the
“parietal” ManLAM used by Nigou et al. [62]; however, one should
keep in mind that more than 90% of ManLAM preparations from
BCG consists of “cellular” ManLAM [62]. A potential reason for the
discrepant results in terms of pro-inﬂammatory responses by
ManLAMmay be differences in the strains fromwhich theManLAM
was isolated. Thus ManLAM derived from M. bovis was shown to
induce pro-inﬂammatory cytokines in DCs at a much lower level
than ManLAM from H37Rv [18]. The ManLAM used by Nigou et al.
was from BCG [62], while the ManLAMs used by Mazurek et al. [18]
and Dulphy et al. [64] were from H37Rv (Table 1). Yet another
reason could be differences in the type of DCs used and protocols to
prepare these cells.
ManLAM has been reported to be unable to trigger IL-10 release
from human blood monocytes [59]. However, ManLAM prepara-
tions from H37Rv induced IL-10 from human DCs in the study by
Mazurek et al. [18] as well as in a study using mouse DC [66]. This
was hardly surprising given that IL-10 is secreted in response toTLR
ligation as well as to high levels of TNF and IL-6 [67] in a negative
feedback manner.
Effect of ManLAM on LPS-activated M4s and DCs
The pro-inﬂammatory molecule LPS [68] is known to drive
maturation of M4s [69] and DCs, and triggers production of pro-
inﬂammatory cytokines [70] such as TNF, IL-6, and IL-12. For this
reason the interaction between ManLAM and LPS has been studied,
and also here the activity of various ManLAM preparations varies in
different experimental setups (Table 3). In early studies Erdman
ManLAM was found to block subsequent LPS-induced M4 activa-
tion [50]. On the other hand a more recent study showed that
H37Rv ManLAM potentiated the LPS-induced expression of CD80,
but not the expression of CD86, or MHC II, and stimulated a mod-
erate but signiﬁcant increase of cytokine production (TNF, IL-6, and
IL-12) in human DCs over that induced by LPS alone [18]. SimilarTable 3
Effect of ManLAM on LPS-induced cytokine production and maturation by M4s and DCs
Publication/year Cell type Strain Origin of Ma
[59] 1996 Monocytes human Erdman/H37Rv CSU
[72] 1998 Human monocyte
derived cell line THP-1
Erdman CSU contract
[61] 2001 DC human BCGy CNRS
[63] 2003 DC human Mtb strain unknown CSU contract
[7] 2004 BMM mouse BCG CNRS
[94] 2005 Raw cell line H37Rv CSU
[71] 2009 DC human Mtb strain unknown CSU
[18] 2012 DC human H37Rv KI
[95] 2013 DC human BCG Not stated
Abbreviations used: BMM e bone marrow derived M4s; CNRS e Centre National de la Rec
e peritoneal M4s.
Symbols used: Increased production; Decreased production; No difference.
* Brackets around arrows mean weak reactions.
y “Cellular” ManLAM, not parietal.
Please cite this article in press as: K€allenius G, et al., Lipoarabinomannan
responses toMycobacterium tuberculosis depending on structural diversit
10.1016/j.tube.2015.09.005observations for IL-12p35, IL-12p40, IL-6 and IL-10 were made by
Gringhuis et al. [71] who found that the production of cytokines
was increased when cells were treated with LPS together with
ManLAM as compared to cells exposed to LPS alone [71]. The
ﬁndings that H37Rv ManLAM provides additional stimuli to the
LPS-induced cytokine secretion, resulting in the augmented cyto-
kine output, suggests that different PRRs on human DCs may be
involved in the ManLAM-as compared to LPS-driven cytokine
responses.
In contrast with these results a paper by Nigou et al. reported
that the “cellular” ManLAM preparation from BCG inhibited IL-12
secretion by human DCs when stimulated with LPS [61]. A similar
negative effect was reported by Knutson et al. [72] making use of a
monocyte cell line. Also reporting a negative effect the study by
Geijtenbeek et al. [63] showed that Mtb ManLAM inhibited LPS-
induced DC maturation.
Immunomodulation induced by LM and PIMs
LMs from different mycobacterial species have been reported to
exhibit contradictory activities, both pro-inﬂammatory and anti-
inﬂammatory responses through TLR2-dependent and -indepen-
dent pathways [7,43,73] (Table 4). LM, including LM puriﬁed from
H37Rv, has been shown to induce IL-12 production in a TLR-2
dependent manner [12] and also inhibit IL-12 production in a
TLR-independent manner [7]. LM (from BCG and Mtb H37Rv) has
been reported to be a strong inducer of TNF through a TLR2
dependent pathway [74], but LM from H37Rv has been also re-
ported to block TNF biosynthesis [75]. LM puriﬁed fromM. chelonae
and Mycobacterium kansasii has been described to induce TNF and
IL-8 secretion through a CD14-TLR2-dependent mechanism [73].
The LM activity appears to depend on the acylation degree [14], on
the length of the mannan chain building the mannopyranosyl
backbone of LM [74] and to be determined by binding to TLR2 [74].
PIM2 and PIM6 are the twomost abundant classes of PIMs found
in Mtb and BCG [76]. In earlier studies non-fractionated PIMs from
H37Ra [15,77] and PIM6 from BCG [14] were reported to stimulate
the production of TNF through TLR2 signalling in M4s [14,15]
(Table 5). According to the authors this effect depended on the
presence of the lipid component of the molecule as de-acylation of
PIM6 abrogated the TNF production [14]. By contrast, in a recent
report, PIM2 and PIM6 from BCG were reported to present anti-
inﬂammatory activities, inhibiting LPS-induced TNF, IL-12, IL-6,
but also inﬂammatory activities by inhibiting IL-10 production in
mouse M4s through a TLR2-independent mechanism [76]. These.
nLAM Cytokine production Maturation (markers)
TNF IL-6 IL-12 IL-10
( )*
NO1 AI-25147 (MHX)
NO1 AI-75320 (CD80, CD83 and CD86)
(CD80)
(CD 86 and MHC II)
herche Scientiﬁque; CSU e Colorado State University; KI e Karolinska Institutet; PM
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Table 4
Activation/maturation of M4s exposed to LM.
Publication/year Cell type Strain Origin of LM TNF IL-12 CD40, CD80 Down-regulation Ligand
[7] 2004 BMM mouse BCG Inhouse
H37Rv CSU/inhouse
[12] 2004 BMM mouse H37Rv CSU TLR2
[96] 2006 BMM mouse and Human
monocyte derived cell line THP-1
BCG CNRS + TLR2
[43] 2007 BMM mouse BCG CNRS ++ ++ ++




[75] 2011 MDM human H37Rv Inhouse Yes
Abbreviations used: BMM e bone marrow derived M4s; CNRS e Centre National de la Recherche Scientiﬁque; CSU e Colorado State University; KI e Karolinska Institutet;
MDM e monocyte derived M4s; PM e peritoneal M4s.
Symbols used: Increased production; Decreased production; No difference;+Dependent on acyl form;++Dependent on acylation form of LM either pro-inﬂammatory
or negative inﬂammatory activity through varying ligands; +++ Activity dependent on mannan chain length of backbone.
Table 5
Activation/maturation and cytokine production of M4s and DCs exposed to PIM.
Publication/year Cell type Strain Origin of PIM Type of PIM Cytokines Activation/maturation Inhibits LPS activation
[49] 1991 PM mouse H37Ra CSU TNF ( )*
[15] 2001 Raw M4 mouse cell line H37Ra CSU TNF ( ) TLR2 agonist
[14] 2003 PM mouse BCG CNRS PIM2 and PIM6 TNF ( ) TLR2 agonist
[12] 2004 BMM mouse H37Rv CSU PIM2 IL-12
[77] 2006 PM mouse H37Rv Inhouse TNF ( )
AM mouse TNF ( )
[76] 2009 BMM mouse BCG CNRS PIM6 ND LPS inhibition
TLR2 independent
TNF, IL-6, IL-12p40
[76] 2009 BMM mouse NA Synthetic PIM2 mimetic ND LPS inhibition
TLR2 independent
TNF, IL-6, IL-12p40
[18] 2012 DC human H37Rv KI TNF, IL-6, IL-12 CD80, CD86 and MHC II TNF, IL-6, IL-12p40
M. bovis KI
Abbreviations used: ATCC e American type culture collection; BMM e bone marrow derived M4s; CNRS e Centre National de la Recherche Scientiﬁque; CSU e Colorado State
University; KI e Karolinska Institutet; PM e Pulmonary M4s.
Symbols used: Increased production; No difference.
* Brackets around arrows mean weak reactions.
G. K€allenius et al. / Tuberculosis xxx (2015) 1e11 7effects were reported to depend on the acylation degree; di-and tri-
acylated PIMs were strongly inhibitory, while tetra-acylated were
less inhibitory, and mono-acylated PIMs were non inhibitory [76].
The observations by Doz et al. of a prominent anti-inﬂammatory
action of PIMs on murine M4s [76] were corroborated and
extended by Mazurek et al. using human DCs [18]. In these studies
PIM2 and total PIM, isolated both from Mtb H37Rv and BCG, were
reported to be potent inhibitors of the LPS-driven activation of
human DCs [18]. PIMs reduced LPS-driven up-regulation of MHC II
but did not modulate LPS-induced expression of the co-stimulatory
molecules CD80 and CD86 [18]. In addition, PIMs also abrogated
ManLAM-elicited augmentation of pro-inﬂammatory cytokine
production (TNF, IL-6 as well as IL-12p40) in LPS-treated DCs [18].
Unlike ManLAM, PIMs alone did not affect surface expression of DC
maturation markers (Table 5). Thus, the inhibition of LPS-induced
cytokine production does not seem to be caused by delayed
maturation/activation of DCs but rather by a down-regulation of
either transcription and/or secretion of those cytokines. PIMs from
M. bovis showed inhibitory activity similar to that of PIMs fromMtb
H37Rv [18]. This is consistent with the fact that the two differently
acylated isoforms of PIM2 and PIM6 are simultaneously present in
both Mtb H37Rv and BCG [78]. More recently synthetic PIM1 and
PIM2 analogues were also shown to inhibit TNF and IL-12p40
expression induced by TLR2 or TLR4 pathways in murine M4s
[76,79]. PIM1 and PIM2 inhibited LPS-induced TNF release by a
CD14-dependent pathway, while IL-12p40 inhibition was
CD14 independent.Please cite this article in press as: K€allenius G, et al., Lipoarabinomannan
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10.1016/j.tube.2015.09.005In conclusion there is clear evidence that certain PIMs from
Mtb H37Rv, M. bovis and BCG are potent anti-inﬂammatory agents
that inhibit the pro-inﬂammatory activity of both LPS and
ManLAM.
Experimental factors potentially relevant for reported
differences in immunomodulation of LAM, LM and PIM
glycolipids
The immune response elicited in vitro by glycolipids is strongly
dependent on the experimental conditions
The type and activation state as well as the origin of cells (hu-
man/animal) chosen for in vitro stimulation experiments may
profoundly affect the ﬁnal outcome. Bradbury and Moreno [51]
examined the action of ManLAM on murine peritoneal and bone
marrow derived M4s and found that only the former produced TNF
in response to H37Rv ManLAM. In accordance, several preparations
of ManLAM from Mtb H37Rv [7,80] and Erdman [57,80] failed to
induce TNF production in murine bone marrow derived M4s. Pre-
sumably mouse bone marrow derived M4s are less “mature” or
more naive than those derived from intraperitoneal sources [81].
Various methods of in vitroM4maturation confer variable capacity
for inﬂammatory responses [82], and it could thus be speculated
that M-CSF, used to propagate M4s from bone marrow, being a
potent regulator of M4 receptors expression, affects the expression
of ManLAM-recognizing receptors [83]., and its related glycolipids, induce divergent and opposing immune
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bind to and signal through various PPRs on host cells. Some of these
molecules bind to TLR2 and/or other TLRs [6e8], while others, such
as ManLAM, are thought to bind DC-speciﬁc C-type lectin DC-SIGN/
CD209 and mannose receptors and to deliver negative signals that
interfere with TLR-mediated signalling [61]. Mycobacterial lip-
oglycans of the LAM/PIM family show a varying degree of TLR2-
dependent pro-inﬂammatory activities [74]. Thus, since PPR
expression is strongly inﬂuenced by the cells used and the protocol
applied to prepare them, one need to pay special attention to this
information when analyzing the data generated.
Other experimental factors that may inﬂuence results are e.g.
time of exposure and amounts of ManLAM used in the treatment
of cells as well as its presentation. Thus for example augmentation
of LPS-induced TNF production was found after short stimulation
(1e4 h) of M4s with ManLAM [59,83], while it was not observed
after prolonged exposure [83]. The stimulation of Dectin-2
receptor with ManLAM induced the production of both pro- and
anti-inﬂammatory cytokines according to its presentation (solu-
ble/plate coated) [66].
Glycolipid puriﬁcation procedures impact on the elicited immune
response
Several procedures have been described by different labora-
tories for the puriﬁcation of LAM and other mycobacterial glyco-
lipids [74,84]. Generally, these procedures rely on the initial
extraction from dried bacterial cells or cell walls with a lipophilic
organic solvent/water system, followed by hydrophobic interaction
and size exclusion chromatography in the presence of a detergent.
These puriﬁcation methods may result in complex glycolipid frac-
tions of varying compositions that are not limited to mannosyl-
terminated glycolipid species alone. In addition, in many in-
stances the puriﬁcation procedure used, and most importantly the
methods used to control the purity of the preparations are not
described.
ManLAM preparations from Colorado State University (CSU)
have over the years been used by many investigators, and are
regarded as the gold standard. During recent years they have been
produced under NIH contracts, as TB Vaccine Testing and Research
Materials (TBVTRM). We recently found that some TBVTRM Man-
LAM preparations were contaminated with other potent immu-
nomodulary molecules that might affect the biological activity of
the preparations [18]. Of two TBVTRM ManLAM lots investigated
both were shown to contain PIMs and also some unidentiﬁed high
molecular weight materials in addition to ManLAM. One TBVTRM
lot tested showed a very high content of glucose suggesting
contamination with mycobacterial glucans. One fraction was most
likely arabinomannan (AM), devoid of most or completely lacking
the lipid (acyl) part of ManLAM [18] (Figure 1).
Altogether the ﬁndings of contaminating materials (glucans,
PIMs) and potential lack of acylation of theManLAM in the TBVTRM
ManLAM preparation described previously [18] may explain some
observations where TBVTRM ManLAM preparations have been
used. Thus mycobacterial glucans have been reported to suppress
IL-12 production in monocyte-derived DCs [85]. The degree of
acylation of mycobacterial glycolipids is important for e.g. the
regulation of pro-inﬂammatory cytokines [14,43,86] so non-
acylated or only partially acylated LAM in a ManLAM preparation
might exert a competitory/inhibitory effect on the ManLAM. High
levels of contaminating anti-inﬂammatory PIMs may also compete
with or inhibit the effects induced by a particular ManLAM lot (see
ahead).
It must also be remembered that all of these studies have
in common the introduction of exogenous isolated ManLAM orPlease cite this article in press as: K€allenius G, et al., Lipoarabinomannan
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10.1016/j.tube.2015.09.005other glycolipid ligands into essentially hydrophilic in vitro as-
says; yet, these are all highly amphipathic with varying degrees of
aqueous compatibility, an important consideration in explaining
contradictory outcomes. Now, with the availability of mutants of
Mtb devoid of key structural/immunogenic aspects of LAM and
LM, a whole bacterium approach can be applied to these ques-
tions [87].
Conclusion
In conclusion, we here review the profound and divergent ef-
fects of the major family of lipoglycans ManLAM, LM and PIMs, on
M4s and DCs with regard to cell maturation and cytokine re-
sponses, and try to conciliate conﬂicting reports about the speciﬁc
properties of these glycolipids. We summarize data showing that
the described discrepancies are associated on one hand with dif-
ferences in glycolipids themselves and/or their preparation, and on
the other hand with differences in the cells used in the
experiments.
With respect to the glycolipids one should keep in mind the
variability in their composition, discrete differences in structure,
the use of glycolipids from different bacterial strains and also dif-
ferences in the protocols used for glycolipid isolation. Part of the
discordant views of LAM stem from early experiments where
AraLAM (withoutmannose cap, and a potent inducer of TNF) that in
early papers [11,36,37] was said to stem from the “avirulent”
attenuated H37Ra strain in fact came from a rapidly growing strain.
Furthermore in some instances the contradictions may have been
caused by the use of LAM preparations that were not sufﬁciently
pure, containing, in addition to LAM, other related biologically
active molecules.
ManLAM presents varying degrees of pro-inﬂammatory capac-
ity, depending on the strain it comes from. ManLAM from the
laboratory strain Mtb Erdman shows extremely low or no pro- and
anti-inﬂammatory activity, compared to ManLAM fromMtb H37Rv.
Some of the low pro-inﬂammatory activities reported for certain
ManLAM preparations may depend on contamination with e.g.
PIMs as a result of the difﬁculty in separating ManLAM and PIM
during the isolation process of ManLAM.
A point seldom recognized is that LAM of whatever ﬂavour, and
LM, as we know them chemically, consist of a heterogeneous
population and the structures presented (e.g. Figure 1) are average
representations. Hence, in order to dissect the role of mycobacteria
derived molecules in innate immune responses the choice of
mycobacterial strain for isolation of the glycolipids is of utmost
importance.
It is conceivable that different LAM/PIM ratios in the cell wall of
different bacterial strains, and during distinct stages of Mtb infec-
tion [47], may be a crucial factor in determining the differential Mtb
stimulation or inhibition of the immune system and thereby be
decisive for the emergence and outcome of the disease [7,16,18].
Some of the discrepant results may be explained by differences
in the cells that were used, such as differences in maturation
(resting or already activated) or receptor equipment (TLR, DC-SIGN,
mannose receptor etc). One early publication by Bradbury and
Moreno [51] clearly illustrates this, where they examined the action
of ManLAM on murine peritoneal and bone marrow derived M4s
and found that only the former produced TNF in response to H37Rv
ManLAM.
Thus, unless head to head experiments are performed, using the
same cells, deﬁnitive conclusions are difﬁcult to achieve regarding
quantitative and even qualitative differences in maturation and
cytokine expression.
It will not be possible or even desirable to achieve full consis-
tency in experiments utilizing lipoglycans and immune cells within, and its related glycolipids, induce divergent and opposing immune
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G. K€allenius et al. / Tuberculosis xxx (2015) 1e11 9this large scientiﬁc ﬁeld. However we think that it is important to
be aware of the discrepancies described here to be able to critically
compare data from distinct sources, to evaluate the relevance of
individual experiments and to design properly future research on
LAM and its related molecules. To be able to do so it is important
that the glycolipids and cells used in the studies are well charac-
terized and that the methods and protocols for preparation of
glycolipids and cells are carefully documented.
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